Anti-Cancer Drugs

Glivec® (imatinib) is indicated for the treatment of patients with CML in blast crisis, accelerated phase, or in chronic phase after failure of IFN- therapy

Chronic Myelogneous Leukemia (CML) is an attractive target for a rationally designed drug development program. The hallmark of CML, the Ph chromosome, contains the specific causative genetic abnormality that results in constitutive activation of the Bcr-Abl tyrosine kinase.

Glivec® targets the molecular cause of CML and is an effective and well-tolerated oral therapy. By inhibiting only the specific cause of the disease, Glivec® brings to fruition the goal of molecularly targeted therapy.

Glivec®, a derivative of 2-phenylaminopyrimidine , is a small molecule antagonist with activity against protein tyrosine kinases. It was chosen because of its potent and specific inhibition of Bcr-Abl.(1-3,5-7)

The Global Product Monograph is available in PDF format at
Glivec® Monograph.